Nektar Therapeutics
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NKTR research report →
Range $50 – $153
Price Chart
About the company
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma.
- CEO
- Howard W. Robin
- IPO
- 1994
- Employees
- 63
- HQ
- San Francisco, CA, US
Get TickerSpark's AI analysis on NKTR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $866.38M
- P/E
- -5.60
- PEG
- -1.36
- P/S
- 19.87
- P/B
- 1.45
- EV/EBITDA
- -6.62
- Div Yield
- 0.00%
- Gross Margin
- 99.71%
- Op Margin
- -301.79%
- Net Margin
- -339.67%
- ROE
- -29.31%
- ROIC
- -15.99%
Latest fiscal year · YoY change
- Revenue
- $55.23M-43.9%
- Gross Profit
- $55.23M-18.5%
- Op Income
- $-130,770,999
- Net Income
- $-164,076,000-37.9%
- EPS
- $-9.73-12.1%
- OCF Growth
- -18.7%
- FCF Growth
- -17.8%
- 52W High
- $109.00
- 52W Low
- $30.13
- 50D MA
- $45.39
- 200D MA
- $64.99
- Beta
- 1.15
- RSI (14)
- 23
- Avg Volume
- 1.11M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Nektar said Q3 was a transformative quarter as REZPEG moved into phase III across atopic dermatitis and alopecia areata, while the company strengthened its cash position and reiterated a long runway to multiple data readouts.· November 12, 2026
- REZPEG entered phase III in atopic dermatitis, with all 3 ZENITH-AD studies initiated and a broad label strategy spanning naive, experienced, monotherapy, and topical corticosteroid combination use.
- The alopecia areata phase III study, ZENITH AA, is now expected to start in December, earlier than previously planned, with first data expected in 2029.
- Management highlighted EADV biomarker data showing early regulatory T-cell signals and correlations with later clinical improvement, supporting the case for REZPEG’s differentiated mechanism.
- The company ended Q3 with approximately $953 million in cash and investments and no debt, and now expects to end 2026 with more than $840 million.
- A new proof-of-concept vitiligo study is planned for about 30 patients, with data expected in late 2027 or early 2028.
Nektar reported third-quarter 2026 non-cash royalty revenue of $8.5 million, R&D expense of approximately $44 million, G&A expense of approximately $25 million, non-cash interest expense of approximately $6 million, and a net loss of approximately $56 million, or $1.63 basic and diluted net loss per share. Cash and investments were approximately $953 million at quarter-end, with no debt. For 2026, management now expects non-cash royalty revenue of approximately $38 million, R&D expense of $185 million to $200 million, G&A expense of approximately $65 million, non-cash interest expense of approximately $28 million, and ending cash and investments of more than $840 million. The company still expects initial top-line data from the AD ZENITH studies in summer 2028, a BLA filing by the end of 2029, and ZENITH AA data in 2029.
Howard Robin framed the quarter as a turning point, emphasizing that REZPEG has advanced from phase II into a full phase III registrational plan. He repeatedly stressed that atopic dermatitis is heterogeneous and that REZPEG’s Treg mechanism could address disease biology more broadly than current IL-13-focused therapies. His tone was confident and strategic, pointing to market demand for novel mechanisms, setbacks in the OX40 class, and the opportunity for REZPEG across immune-mediated diseases beyond dermatology.
Linda Rubinstein’s update focused on balance sheet strength and a rising spend profile as clinical activity ramps. She said Nektar ended Q3 with approximately $953 million in cash and investments and no debt, and now expects to end 2026 with more than $840 million, above the prior range of $815 million to $840 million. She also gave specific cost guidance: Q3 R&D was about $44 million, full-year R&D is now expected at $185 million to $200 million, Q3 G&A was about $25 million, full-year G&A is expected to be about $65 million, and non-cash interest is expected to be about $28 million for the year.
Analysts focused heavily on study design, including why ZENITH AD-2 was changed to include topical corticosteroids, whether sample size or power changed, and how the company is thinking about naive versus experienced patients. Management said the protocol change reflected combined feedback from the FDA, EMA, and PMDA, and that the broader design is intended to support the broadest possible label. Questions also centered on off-treatment durability in REZOLVE-AD and ZENITH AA; management said REZOLVE-AD has 125 patients in the off-treatment follow-up, while ZENITH AA will move responders into monthly or quarterly maintenance dosing rather than a withdrawal design. Analysts also pressed on vitiligo study design and patient selection, and management said the planned proof-of-concept study will enroll active non-segmental vitiligo patients and is still being finalized.
The call reinforced that REZPEG is moving deeper into registrational development with multiple shots on goal: atopic dermatitis, alopecia areata, and a new vitiligo proof-of-concept study. Management pointed to biomarker data, durability signals, and regulatory alignment as reasons to believe the drug could support infrequent dosing and a differentiated profile. The company also has a large cash balance and no debt, reducing near-term financing pressure.
The main risk remains that the company is still years away from key efficacy readouts, with AD data not expected until summer 2028 and alopecia data in 2029. Much of the bull case depends on phase III confirming durability and broad efficacy across patient groups, including previously treated patients and combination use. The company is also increasing spending as enrollment and startup activities accelerate, and management acknowledged that registration will still depend on success across a very large and complex phase III package.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 101.6%
- Shares Outstanding
- 28.69M
- Float Shares
- 29.14M
of shares held by institutions
261 13F filers
Buy/sell ratio 6.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for NKTR, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 5.12M | ▲ 53.52K |
| Two Seas Capital LP | 3.35M | ▲ 253.74K |
| Blackrock, Inc. | 2.87M | ▼ 70.39K |
| Bvf Inc/Il | 2.39M | ▼ 168.52K |
| State Street Corp | 1.77M | ▲ 862.62K |
| Vanguard Capital Management LLC | 1.50M | ▲ 4.76K |
| Two Sigma Investments, LP | 1.20M | ▲ 271.26K |
| Vanguard Group Inc | 1.03M | ▲ 78.44K |
| Vestal Point Capital, LP | 1.00M | ▲ 715.00K |
| Geode Capital Management, LLC | 891.93K | ▲ 10.62K |
| Morgan Stanley | 830.21K | ▼ 106.35K |
| Prosight Management, LP | 785.00K | ▼ 25.00K |
Held by 228 ETFs
Biggest fund positions in NKTR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | ROBIN HOWARD W | sell | 429 |
| Nov 17, 26 | Zalevsky Jonathan | sell | 192 |
| Sep 23, 26 | WHITFIELD ROY A | other | 2,000 |
| Sep 23, 26 | WHITFIELD ROY A | other | 4,000 |
| Sep 23, 26 | GREER R SCOTT | other | 2,000 |
| Sep 23, 26 | GREER R SCOTT | other | 4,000 |
| Sep 23, 26 | CHESS ROBERT | other | 2,000 |
| Sep 23, 26 | CHESS ROBERT | other | 4,000 |
| Sep 23, 26 | Brainard Diana | other | 4,000 |
| Sep 23, 26 | Brainard Diana | other | 2,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NKTR coverage
Recent articles, reports, and earnings notes.
Want a deeper read on NKTR?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Nektar Therapeutics (NKTR) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 17
NKTR Q3 Earnings Beat Estimates, 2026 Revenue View Cut, Stock Down
zacks.com · Nov 13
Nektar Therapeutics (NKTR) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 13
What Nektar Therapeutics (NKTR) Said on Its Q3 Earnings Call
marketbeat.com · Nov 12
Nektar Therapeutics (NKTR) Reports Q3 Loss, Lags Revenue Estimates
zacks.com · Nov 12
Nektar Therapeutics Announces Third Quarter 2026 Financial Results
prnewswire.com · Nov 12
Nektar Therapeutics to Participate in Two Investor Conferences in November
prnewswire.com · Nov 11
CenterBook Partners LP Buys 26,346 Shares of Nektar Therapeutics $NKTR
defenseworld.net · Nov 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
